References
- Zhang Y, Dai Y, Zheng T, et al. Risk factors of non-Hodgkin lymphoma. Expert Opin Med Diagn 2011;5:539–550.
- Ekström-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma—a review. Acta Oncol 2006;45:258–271.
- Cabanillas F. Non-Hodgkin's lymphoma: the old and the new. Clin Lymphoma Myeloma Leuk 2011;11(Suppl. 1):S87–S90.
- Martelli M, Ferreri AJ, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013;87:146–171.
- The International non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
- Chen WL, Tsai WC, Chao TY, et al. The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann Hematol 2010;89:553–562.
- Zhang Y, Chen MB, Zhou XY, et al. Lymphotoxin alpha (LTA) polymorphism is associated with porgnosis of non-Hodgkin's lymphoma in a Chinese population. PLoS One 2013;8:e66411.
- Wrobel T, Mazur G, Dzietczenia J, et al. VEGF and bFGF gene polynorphisms in patients with non-Hodgkin's lymphoma. BioMed Res Int 2013;2013:159813.
- Ferlazzo G, Thomas D, Lin SL, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004;172: 1455–1462.
- Khalaf R, Hoteit R, Yazbek S, et al. Natural killer cell immunoglobulin-like receptor (KIR) in follicular lymphoma patients: results of a pilot study. Gene 2013;525:136–140.
- Babor F, Fischer JC, Uhrberg M. The role of KIR genes and ligands in leukemia surveillance. Front Immunol 2013;4:1–10.
- Young NT, Uhrberg M. KIR expression shapes cytotoxic repertoires: a developmental program of survival. Trends Immunol 2002;23:71–75.
- Haedick W, Ho FC, Chott A, et al. Expression of CD94/NKG2A and killer immunoglobulin-like receptors in NK cells and a subset of extranodal cytotoxic T-cell lymphomas. Blood 2000;95:3628–3630.
- Marsh SG, Parham P, Dupont B, et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Hum Immunol 2003;64:648–654.
- Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002;20:217–251.
- Stern M, Opelz G, Döhler B, et al. Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood 2010;115:3960–3965.
- Morice WG, Macon WR, Dogan A, et al. NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis. Leukemia 2006;20:883–886.
- Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
- Karabon L, Jedynak A, Giebel S, et al. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens 2011;78:129–138.
- Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009;113:3119–3129.
- Yu J, Heller G, Chewning J, et al. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 2007;179: 5977–5989.
- Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005;5:201–214.
- Passweg JR, Huard B, Tiercy JM, et al. HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends Immunol 2007;28:437–441.
- Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008;22:249–257.
- Middleton D, Diler AS, Meenagh A, et al. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) presence of their ligand (HLA-C1 group) protect against chronic myeloid leukemia. Tissue Antigens 2009;73:553–560.
- Alcoceba M, Sebastian E, Marín L, et al. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood 2013;122:1448–1454.